INVA: Specialty therapeutics and innovative drug delivery drive growth, with resilient royalty streams funding expansion
Specialty therapeutics revenue exceeded $200 million, driven by XACDURO and GIAPREZA, with strong U.S. and ex-U.S. growth. Nortiva's LYNX platform targets once-monthly oral contraceptives, supported by the Gates Foundation, and broad drug reformulation potential. Royalty streams remain resilient, f…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.